K
Keith M. Sullivan
Researcher at Duke University
Publications - 458
Citations - 40788
Keith M. Sullivan is an academic researcher from Duke University. The author has contributed to research in topics: Transplantation & Total body irradiation. The author has an hindex of 105, co-authored 447 publications receiving 39067 citations. Previous affiliations of Keith M. Sullivan include American Cancer Society & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
Richard A. Nash,Richard A. Nash,Peter A. McSweeney,Leslie J. Crofford,Muneer H. Abidi,Chien-Shing Chen,J. David Godwin,Ted Gooley,Ted Gooley,Leona Holmberg,Leona Holmberg,Gretchen Henstorf,C. Fred LeMaistre,Maureen D. Mayes,Kevin T. McDonagh,Bernadette McLaughlin,Jerry A. Molitor,J. Lee Nelson,J. Lee Nelson,Howard M. Shulman,Howard M. Shulman,Rainer Storb,Rainer Storb,Federico Viganego,Mark H. Wener,James R. Seibold,Keith M. Sullivan,Daniel E. Furst +27 more
TL;DR: Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies, and HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial.
Journal ArticleDOI
Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment
Robert P. Witherspoon,R Storb,HansD. Ochs,N Fluornoy,Kenneth J. Kopecky,Keith M. Sullivan,Joachim Deeg,R Sosa,Noel,K Atkinson,Thomas Ed +10 more
TL;DR: The data indicate that, given enough time after transplantation, the ability to produce normal antibody function recovers except in those patients experiencing chronic GVHD.
Journal ArticleDOI
Obstructive Lung Disease after Allogeneic Marrow Transplantation: Clinical Presentation and Course
TL;DR: Obstructive lung disease was frequently associated with serum immunoglobulin deficiency and clinical, extensive, chronic graft-versus-host disease that was not readily responsive to treatment.
Journal ArticleDOI
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients
Rainer Storb,Kristine Doney,Thomas Ed,FR Appelbaum,Buckner Cd,Reginald A. Clift,H. J. Deeg,BW Goodell,Robert C. Hackman,John A. Hansen,Jean E. Sanders,Keith M. Sullivan,Paul L. Weiden,Robert P. Witherspoon +13 more
TL;DR: The addition of buffy coat cell infusions to the marrow inoculum reduced the risk of rejection and increased survival in the currently reported transfused patients when compared to patients grafted before 1976, however, there was an increased risk of chronic GVHD.
Journal ArticleDOI
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment
Mitchell E. Horwitz,Nelson J. Chao,David A. Rizzieri,Gwynn D. Long,Keith M. Sullivan,Cristina Gasparetto,John P. Chute,Ashley Morris,Carolyn McDonald,Barbara Waters-Pick,Patrick J. Stiff,Steven Wease,Amnon Peled,David Snyder,Einat Galamidi Cohen,Hadas Shoham,Efrat Landau,Etty Friend,Iddo Peleg,Dorit Aschengrau,Dima Yackoubov,Joanne Kurtzberg,Tony Peled +22 more
TL;DR: If long-term safety is confirmed, NiCords has the potential to broaden accessibility and reduce the toxicity of UCB transplantation, and the results justify further study of NiCord transplantation as a single UCB graft.